Association between inflammatory biomarker profiles and cardiovascular risk in individuals with and without HIV.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
15 03 2023
15 03 2023
Historique:
pubmed:
22
12
2022
medline:
25
2
2023
entrez:
21
12
2022
Statut:
ppublish
Résumé
People with HIV have an increased risk for cardiovascular morbidity and mortality. Inflammation and immune activation may contribute to this excess risk. We assessed thirty-one biomarkers in a subset of POPPY participants and identified three distinct inflammatory profiles: 'gut/immune activation', 'neurovascular', and 'reference' (relatively low levels of inflammation). Ten-year cardiovascular disease (CVD) risk predictions were calculated using the QRISK, Framingham Risk Score (FRS) and the Data Collection on Adverse effects of anti-HIV Drugs (D:A:D) algorithms. The distributions of CVD risk scores across the different inflammatory profiles, stratified by HIV status, were compared using median quantile regression. Of the 312 participants included [70% living with HIV, median (interquartile range; IQR) age 55 (51-60) years; 82% male; 91% white], 36, 130, and 146 were in the 'gut/immune activation', 'neurovascular', and 'reference' cluster, respectively. The median (IQR) QRISK scores were 9.3% (4.5-14.5) and 10.2% (5.5-16.9) for people with and without HV, respectively, with similar scores obtained with the FRS and D:A:D. We observed statistically significant differences between the distributions of scores in the three clusters among people with HV. In particular, median QRISK [5.8% (1.0-10.7) and 3.1% (0.3-5.8)] scores were higher, respectively, for those in the 'gut/immune activation' and 'neurovascular' clusters compared to those in the reference cluster. People with HIV with increased gut/immune activation have a higher CVD risk compared to those with relatively low inflammation. Our findings highlight that clinically important inflammatory subgroups could be useful to differentiate risk and maximise prediction of CVD among people with HIV.
Sections du résumé
BACKGROUND
People with HIV have an increased risk for cardiovascular morbidity and mortality. Inflammation and immune activation may contribute to this excess risk.
METHODS
We assessed thirty-one biomarkers in a subset of POPPY participants and identified three distinct inflammatory profiles: 'gut/immune activation', 'neurovascular', and 'reference' (relatively low levels of inflammation). Ten-year cardiovascular disease (CVD) risk predictions were calculated using the QRISK, Framingham Risk Score (FRS) and the Data Collection on Adverse effects of anti-HIV Drugs (D:A:D) algorithms. The distributions of CVD risk scores across the different inflammatory profiles, stratified by HIV status, were compared using median quantile regression.
RESULTS
Of the 312 participants included [70% living with HIV, median (interquartile range; IQR) age 55 (51-60) years; 82% male; 91% white], 36, 130, and 146 were in the 'gut/immune activation', 'neurovascular', and 'reference' cluster, respectively. The median (IQR) QRISK scores were 9.3% (4.5-14.5) and 10.2% (5.5-16.9) for people with and without HV, respectively, with similar scores obtained with the FRS and D:A:D. We observed statistically significant differences between the distributions of scores in the three clusters among people with HV. In particular, median QRISK [5.8% (1.0-10.7) and 3.1% (0.3-5.8)] scores were higher, respectively, for those in the 'gut/immune activation' and 'neurovascular' clusters compared to those in the reference cluster.
CONCLUSIONS
People with HIV with increased gut/immune activation have a higher CVD risk compared to those with relatively low inflammation. Our findings highlight that clinically important inflammatory subgroups could be useful to differentiate risk and maximise prediction of CVD among people with HIV.
Identifiants
pubmed: 36541572
doi: 10.1097/QAD.0000000000003462
pii: 00002030-202303150-00005
pmc: PMC9994838
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
595-603Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators . N Engl J Med 1998; 338:853–860.
Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d’Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study . Lancet 2003; 362:22–29.
Croxford S, Kitching A, Desai S, Kall M, Edelstein M, Skingsley A, et al. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort . Lancet Public Health 2017; 2:e35–e46.
Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis . HIV Med 2012; 13:453–468.
Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, Sax PE, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy . Circulation 2008; 118:e29–e35.
Baker JV, Lundgren JD. Cardiovascular implications from untreated human immunodeficiency virus infection . Eur Heart J 2011; 32:945–951.
Pereyra F, Lo J, Triant VA, Wei J, Buzon MJ, Fitch KV, et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers . AIDS 2012; 26:2409–2412.
Gooden TE, Gardner M, Wang J, Jolly K, Lane DA, Benjamin LA, et al. Incidence of cardiometabolic diseases in people living with and without HIV in the UK: a population-based matched cohort study . J Infect Dis 2021; 255:1348–1356.
So-Armah K, Freiberg MS. HIV and cardiovascular disease: update on clinical events, special populations, and novel biomarkers . Curr HIV/AIDS Rep 2018; 15:233–244.
Tien PC, Choi AI, Zolopa AR, Benson C, Tracy R, Scherzer R, et al. Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort . J Acquir Immune Defic Syndr 2010; 55:316–322.
Hsue PY, Hunt PW, Schnell A, Kalapus SC, Hoh R, Ganz P, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis . AIDS 2009; 23:1059–1067.
Secemsky EA, Scherzer R, Nitta E, Wu AH, Lange DC, Deeks SG, et al. Novel biomarkers of cardiac stress, cardiovascular dysfunction, and outcomes in HIV-infected individuals . JACC Heart Fail 2015; 3:591–599.
Vos AG, Idris NS, Barth RE, Klipstein-Grobusch K, Grobbee DE. Pro-inflammatory markers in relation to cardiovascular disease in HIV infection. A systematic review . PLoS One 2016; 11:e0147484.
Titanji B, Gavegnano C, Hsue P, Schinazi R, Marconi VC. Targeting inflammation to reduce atherosclerotic cardiovascular risk in people with HIV infection . J Am Heart Assoc 2020; 9:e014873.
Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study . BMJ 2007; 335:136.
Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles . Am Heart J 1991; 121 (1 Pt 2):293–298.
Laurence J, Elhadad S, Robison T, Terry H, Varshney R, Woolington S, et al. HIV protease inhibitor-induced cardiac dysfunction and fibrosis is mediated by platelet-derived TGF-β1 and can be suppressed by exogenous carbon monoxide . PLoS One 2017; 12:e0187185.
Laurence J, Elhadad S, Ahamed J. HIV-associated cardiovascular disease: importance of platelet activation and cardiac fibrosis in the setting of specific antiretroviral therapies . Open Heart 2018; 5:e000823.
Bakewell N, Sabin CA, Negi R, Garcia-Leon A, Winston A, Sachikonye M, et al. Biomarker associations with insomnia and secondary sleep outcomes in persons with and without HIV in the POPPY-Sleep sub-study: a cohort study . Sleep 2022.
Bagkeris E, Burgess L, Mallon PW, Post FA, Boffito M, Sachikonye M, et al. Cohort profile: the Pharmacokinetic and clinical Observations in People over Fifty (POPPY) study . Int J Epidemiol 2018; 47:1391–1392e.
Kunisaki KM, De Francesco D, Sabin CA, Winston A, Mallon PWG, Anderson J, et al. Sleep disorders in human immunodeficiency virus: a substudy of the Pharmacokinetics and Clinical Observations in People over Fifty (POPPY) study . Open Forum Infect Dis 2021; 8:ofaa561.
Dhillon S, Sabin CA, Alagaratnam J, Bagkeris E, Post FA, Boffito M, et al. Level of agreement between frequently used cardiovascular risk calculators in people living with HIV . HIV Med 2019; 20:347–352.
van Zoest RA, Law M, Sabin CA, Vaartjes I, van der Valk M, Arends JE, et al. Predictive performance of cardiovascular disease risk prediction algorithms in people living with HIV . J Acquir Immune Defic Syndr 2019; 81:562–571.
Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities . Nat Rev Microbiol 2012; 10:655–666.
Trøseid M, Manner IW, Pedersen KK, Haissman JM, Kvale D, Nielsen SD. Microbial translocation and cardiometabolic risk factors in HIV infection . AIDS Res Hum Retroviruses 2014; 30:514–522.
Burgel PR, Paillasseur JL, Caillaud D, Tillie-Leblond I, Chanez P, Escamilla R, et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses . Eur Respir J 2010; 36:531–539.
Erro R, Vitale C, Amboni M, Picillo M, Moccia M, Longo K, et al. The heterogeneity of early Parkinson's disease: a cluster analysis on newly diagnosed untreated patients . PLoS One 2013; 8:e70244–e170244.
McGettrick P, Tinago W, Garcia-Leon A, O’Brien JOB, Mahon N, Lawler L, et al. Biological profiles predict coronary artery disease in PWH and risk-matched controls . Conference on Retroviruses and Opportunistic Infections (CROI) 2021.
Mooney S, Tracy R, Osler T, Grace C. Elevated biomarkers of inflammation and coagulation in patients with HIV are associated with higher Framingham and VACS Risk Index Scores . PLoS One 2015; 10:e0144312.
Subramanya V, McKay HS, Brusca RM, Palella FJ, Kingsley LA, Witt MD, et al. Inflammatory biomarkers and subclinical carotid atherosclerosis in HIV-infected and HIV-uninfected men in the Multicenter AIDS Cohort Study . PLoS One 2019; 14:e0214735.
Rodriguez VJ, Abbamonte JM, Parrish MS, Jones DL, Weiss S, Pallikkuth S, et al. Predicting cardiovascular risk using a novel risk score in young and middle-age adults with HIV: associations with biomarkers and carotid atherosclerotic plaque . Int J STD & AIDS 2021; 33:144–155.
Lichtfuss GF, Hoy J, Rajasuriar R, Kramski M, Crowe SM, Lewin SR. Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection . Biomark Med 2011; 5:171–186.
Munford RS. Endotoxemia-menace, marker, or mistake? . J Leukoc Biol 2016; 100:687–698.